- Home
- RIVN vs NBIX Comparison
RIVN vs NBIX Comparison
Compare RIVN & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIVN
- NBIX
- Stock Information
- Founded
- RIVN 2009
- NBIX 1992
- Country
- RIVN United States
- NBIX United States
- Employees
- RIVN N/A
- NBIX N/A
- Industry
- RIVN Auto Manufacturing
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RIVN Consumer Discretionary
- NBIX Health Care
- Exchange
- RIVN Nasdaq
- NBIX Nasdaq
- Market Cap
- RIVN 13.3B
- NBIX 13.1B
- IPO Year
- RIVN 2021
- NBIX 1996
- Fundamental
- Price
- RIVN $14.11
- NBIX $138.71
- Analyst Decision
- RIVN Buy
- NBIX Buy
- Analyst Count
- RIVN 23
- NBIX 23
- Target Price
- RIVN $15.67
- NBIX $165.00
- AVG Volume (30 Days)
- RIVN 42.4M
- NBIX 884.4K
- Earning Date
- RIVN 11-07-2024
- NBIX 02-05-2025
- Dividend Yield
- RIVN N/A
- NBIX N/A
- EPS Growth
- RIVN N/A
- NBIX 97.40
- EPS
- RIVN N/A
- NBIX 3.73
- Revenue
- RIVN $4,551,000,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- RIVN $6.31
- NBIX $27.07
- Revenue Next Year
- RIVN $9.21
- NBIX $16.60
- P/E Ratio
- RIVN N/A
- NBIX $36.67
- Revenue Growth
- RIVN 20.33
- NBIX 25.72
- 52 Week Low
- RIVN $8.26
- NBIX $110.95
- 52 Week High
- RIVN $24.62
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- RIVN 63.27
- NBIX 73.61
- Support Level
- RIVN $13.23
- NBIX $125.61
- Resistance Level
- RIVN $15.49
- NBIX $130.48
- Average True Range (ATR)
- RIVN 0.88
- NBIX 2.67
- MACD
- RIVN 0.19
- NBIX 0.90
- Stochastic Oscillator
- RIVN 69.81
- NBIX 95.47
About RIVN Rivian Automotive Inc.
Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.